engage checkpoint medical linkedin twitter

Drug Therapies Post-ACS

Drug Therapies Post-ACS

Prof. Dr Kurt Huber

Portrait of Kurt Huber
Prof. Dr Kurt Huber


Klinik Ottakring


preview next

time Webinar | open 15 min | Sep 2021

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Antithrombotic treatment with and without invasive management is a fundamental component of ACS management. While dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events in patients with ACS, the combination and time of initiation should reflect the ischaemic and bleeding risk of the patient. Other pharmacological therapies for long term maintenance after an ACS event include high-intensity lipid lowering agents, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) and beta blockers.

Learn more about these drug therapy strategies from Prof. Dr. Kurt Huber. View his presentation from the ACS Forum 2020 webinar and download the accompanying slides for more information. This educational content is relevant for cardiologists, including interventional cardiologists, as well as primary care physicians.

To continue your educational journey, follow the link above to view the complete on-demand video recording of the ACS Forum 2020 webinar. At this link you can also access the accredited e-learning designed around the ACS Forum programme.

The ACS Forum is a medical educational programme supported by an Independent Educational Grant from Amgen.

CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.

Other programmes of interest

preview next